Edesa Biotech reports developments as a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases. Its recurring news centers on paridiprubart, or EB05, an anti-TLR4 antibody evaluated for Acute Respiratory Distress Syndrome, and EB06, an anti-CXCL10 monoclonal antibody program for moderate-to-severe nonsegmental vitiligo.
Company updates also cover clinical data presentations, manufacturing and regulatory preparation, government-supported research activities, conference participation, operating results, capital-structure matters and shareholder governance. Financial reports generally frame spending around clinical development priorities and the company’s monoclonal antibody pipeline.
Edesa Biotech (NASDAQ:EDSA) reported Q3 and YTD financial results for the period ending June 30, 2020. The company obtained Canadian approval for a Phase 2/3 study of EB05, targeting COVID-19 patients' ARDS. Edesa's total revenues reached $0.11 million for Q3, while net loss was $1.77 million ($0.20 per share). For 9 months, revenues were $0.33 million, with a net loss of $4.35 million ($0.52 per share). Cash and equivalents stood at $5.64 million at the end of Q3, bolstered by $2.42 million from warrant exercises. Edesa aims to expand its study to U.S. hospitals and prepare for increased patient enrollment.